[接受综合治疗的高级别胶质瘤患者的生存分析]
[Survival analysis for high-grade glioma patients who received comprehensive treatment].
作者信息
Liu Guiyun, Jiang Rong, Xu Chenyang, Zhou Jiao, Liu Fengxin, He Zhengwen, Liu Zhigang
机构信息
Department of Clinical Medicine, South China University of Medicine, Hengyang Hunan 421001; Department of Radiotherapy, Hunan Cancer Hospital and Affi liated Cancer Hospital of Xiangya School of Medicine, Central South University; Key Laboratory of Translational Radiation Oncology, Changsha 410013, China.
Department of Neurosurgery, Hunan Cancer Hospital, Affi liated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
出版信息
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2018 Apr 28;43(4):388-393. doi: 10.11817/j.issn.1672-7347.2018.04.008.
To analyze the curative effect and prognostic factors for comprehensive therapy in patients with high-grade glioma. Methods: Patients with high-grade glioma (WHO grade III, grade IV) were chosen from July 2008 to May 2016 in the Hunan Cancer Hospital, and a retrospective analysis was performed in 64 patients with complete follow-up data. Results: The follow-up time was 3-111 (median 29.5) months, the median overall survival time was 36.00 (95% CI 22.85 to 49.16) months, the median progression-free survival time (PFS) was 21.00 (95% CI 9.72 to 32.28) months. The 1-year, 2-year, 3-year and 5-year survival rates of high-grade glioma patients were 87.50%, 56.25%, 40.63% and 17.19%, respectively. The univariate analysis of Log-Rank test and the Cox regression model analysis showed that the prognostic factors related to the prognosis of high-grade glioma patients were pathological grade, resection degree, and concurrent chemo-radiotherapy (P<0.05). Conclusion: The overall survival time, progression-free survival time and the 5-year survival rate of patients with high-grade glioma after comprehensive treatment is partially improved. The factors relevant to the prognosis of patients with high-grade glioma are pathological grade, resection degree, and concurrent chemo-radiotherapy, indicating that the glioma patients (WHO grade III) received total resection of the tumor and concurrent chemo-radiotherapy have better clinical effect.
分析高级别胶质瘤患者综合治疗的疗效及预后因素。方法：选取2008年7月至2016年5月在湖南省肿瘤医院就诊的高级别胶质瘤（WHOⅢ级、Ⅳ级）患者，对64例有完整随访资料的患者进行回顾性分析。结果：随访时间为3 - 111（中位29.5）个月，中位总生存时间为36.00（95%CI 22.85至49.16）个月，中位无进展生存时间（PFS）为21.00（95%CI 9.72至32.28）个月。高级别胶质瘤患者的1年、2年、3年和5年生存率分别为87.50%、56.25%、40.63%和17.19%。Log-Rank检验单因素分析及Cox回归模型分析显示，与高级别胶质瘤患者预后相关的预后因素为病理分级、切除程度及同步放化疗（P<0.05）。结论：高级别胶质瘤患者综合治疗后的总生存时间、无进展生存时间及5年生存率有部分提高。与高级别胶质瘤患者预后相关的因素为病理分级、切除程度及同步放化疗，提示胶质瘤（WHOⅢ级）患者行肿瘤全切除并同步放化疗有较好的临床效果。
Zotero 插件